Sunesis Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 77   

Articles published

SNSS 1.70 +0.01 (0.59%)
price chart
Ahead of the Bell: Sunesis Pharma shares sink
Sunesis said it will seek marketing approval from European regulators and also will meet with the U.S. Food and Drug Administration to determine the "appropriate regulatory path forward.
An Insight Into Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS)  Inside Trade
Sunesis Announces Results From Pivotal Phase 3 VALOR Trial of Vosaroxin ...  MarketWatch
Related articles »  
Could Sunesis Pharmaceuticals, Inc.(NASDAQ:SNSS), Resolute Energy Corp ...
Sunesis Pharmaceuticals, Inc.(NASDAQ:SNSS) is a California-based biopharmaceutical company that develops and commercializes oncology therapeutics for the treatment of both solid and hematologic cancers.
Stocks to Keep Your Eyes on - Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS ...  Techsonian (press release)
Morning Buzz: MannKind Corp. (NASDAQ:MNKD), Sunesis Pharmaceuticals ...  Gaining Green
Related articles »  
Short Interest: JDS Uniphase Corporation (JDSU), Adobe Systems (ADBE ...
Recent short interest data for the 9/30/2014 settlement date shows an increase in short interest for shares of Sunesis Pharmaceuticals, Inc. (SNSS). As of September 30, the short interest for the biopharmaceutical company totaled 10,826,791 shares, ...
Sunesis Pharmaceuticals Inc. (SNSS) Hits New 52-week Low During October 10 ...
Sunesis Pharmaceuticals Inc. (SNSS) established a new 52-week low yesterday, and could be a company to watch at the open. After opening at $1.22, Sunesis Pharmaceuticals Inc. dropped to $1.05 for a new 52-week low. By the closing bell, the company's ...
Related articles »  
Short Interest in Sunesis Pharmaceuticals Drops By 43.1% (SNSS)
Currently, 13.4% of the shares of the company are short sold. SNSS has been the subject of a number of recent research reports.
Sunesis Pharmaceuticals Down on Failure of Trial on Qinprezo
Shares of Sunesis Pharmaceuticals, Inc. (SNSS) plunged significantly after the company announced that its phase III trial, VALOR, failed to meet its primary endpoint.
Sunesis Pharmaceuticals Inc. (SNSS) Drops 78.01% on October 6
Sunesis Pharmaceuticals Inc. (SNSS) was one of the Russell 2000's biggest losers for October 6 as the stock slid 78.01% to $1.46, a loss of $5.18 per share.
The Zacks Analyst Blog Highlights: Sunesis Pharmaceuticals, Chimerix ...
Last week, companies like Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS-Free Report) and Chimerix, Inc. (Nasdaq: CMRX-Free Report) were in the news due to pipeline updates.
Related articles »  
Most Active Buzz: Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS), PDL ...
Lakeway, NY - (MARKET NEWS CALL) - 10/27/2014�, an investment community with a special focus on updating investors with recent news on the U.S.
Related articles »  
Stocks in the News � Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS), General ...
Manhattan, NY- 28 October, 2014 - (Techsonian) - Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) released the presentation of updated results from an ongoing Phase 1b/2 University of Texas MD Anderson Cancer Center-sponsored trial of Qinprezo(TM) ...